Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4567-4578

  Popovics, Petra ^a,b,d   Schally, Andrew V ^a,b   Szalontay, Luca ^a   Block, Norman L ^a,b   Rick, Ferenc G ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

CRPC; Cytotoxic peptide analog; GnRH; Hormone naive prostate cancer; LHRH agonist; Reactive oxygen species; Targeted therapy

Indexed keywords

DOXORUBICIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN RECEPTOR; HISTONE GAMMA H2AX; HISTONE H2AX; PROTEIN P21; PROTEIN P62; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ZOPTARELIN DOXORUBICIN; [DEXTRO LYSINE(6)]LUTEINIZING HORMONE RELEASING HORMONE; LHRH, LYSINE(6)-DOXORUBICIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENCY; DRUG UPTAKE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REACTIVE OXYGEN SPECIES; RECEPTORS, LHRH; RHO GTP-BINDING PROTEINS;

EID: 84905113457     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2146     Document Type: Article

References (70)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1): 9-29.
2. Rick FG, Block NL and Schally AV. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert opinion on pharmacotherapy. 2013; 14(16): 2237-2247.
3. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, Zhang A, Xia X, Ilkayeva OR, Xin L, Ittmann MM, Rick FG, Schally AV and Frigo DE. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch. Oncogene. 2013.
4. Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV and Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci U S A. 2014; 111(3): 1084-1089.
5. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2008; 40(5): 315-322.
6. Thompson IM, Zeidman EJ and Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. The Journal of urology. 1990; 144(6): 1479-1480.
7. Cook T and Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. The oncologist. 2000; 5(2): 162-168.
8. Shore ND. Experience with degarelix in the treatment of prostate cancer. Therapeutic advances in urology. 2013; 5(1): 11-24.
9. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes Garcia M, Cardenas-Cornejo I, Graef-Sanchez A, Comaru-Schally AM and Schally AV. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. The Prostate. 1994; 24(2): 84-92.
10. Rick FG, Block NL and Schally AV. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. OncoTargets and therapy. 2013; 6: 391-402.
11. Heidenreich A, Pfister D, Merseburger A, Bartsch G and German Working Group on Castration-Resistant Prostate C. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. European urology. 2013; 64(2): 260-265.
12. Garcia JA and Rini BI. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer. 2012; 118(10): 2583-2593.
13. Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L and Rick FG. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget. 2013; 4(3): 422-432.
14. Rick FG, Saadat SH, Szalontay L, Block NL, Kazzazi A, Djavan B and Schally AV. Hormonal manipulation of benign prostatic hyperplasia. Current opinion in urology. 2013; 23(1): 17-24.
15. Rick FG, Schally AV, Block NL, Abi-Chaker A, Krishan A and Szalontay L. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia. The Prostate. 2013; 73(8): 873-883.
16. Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I and Szalontay L. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 2011; 71(7): 736-747.
17. Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M and Rekasi Z. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol. 2012; 187(4): 1498-1504.
18. Volker P, Grundker C, Schmidt O, Schulz KD and Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. American journal of obstetrics and gynecology. 2002; 186(2): 171-179.
19. Imai A, Ohno T, Iida K, Fuseya T, Furui T and Tamaya T. Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer. 1994; 74(9): 2555-2561.
20. Friess H, Buchler M, Kiesel L, Kruger M and Beger HG. LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas. International journal of pancreatology: official journal of the International Association of Pancreatology. 1991; 10(2): 151-159.
21. Bahk JY, Kim MO, Park MS, Lee HY, Lee JH, Chung BC and Min SK. Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation. Urologia internationalis. 2008; 80(4): 431-438.
22. Baumann KH, Kiesel L, Kaufmann M, Bastert G and Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast cancer research and treatment. 1993; 25(1): 37-46.
23. Halmos G, Arencibia JM, Schally AV, Davis R and Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. The Journal of urology. 2000; 163(2): 623-629.
24. Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, BrockhoffG, Ortmann O, Diedrich K and Koster F. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol. 2009; 35(4): 789-796.
25. Hohla F, Winder T, Greil R, Rick FG, Block NL and Schally AV. Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World journal of gastroenterology: WJG. 2014; 20(20): 6102-6112.
26. Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J and Pinski J. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(18): 4675-4680.
27. Schally AV and Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. European journal of endocrinology/European Federation of Endocrine Societies. 1999; 141(1): 1-14.
28. Schally AV and Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends in endocrinology and metabolism: TEM. 2004; 15(7): 300-310.
29. Letsch M, Schally AV, Szepeshazi K, Halmos G and Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(12): 4505-4513.
30. Liu SV, Liu S and Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert opinion on investigational drugs. 2011; 20(6): 769-778.
31. Engel JB, Schally AV, Dietl J, Rieger L and Honig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Molecular pharmaceutics. 2007; 4(5): 652-658.
32. Emons G, Kaufmann M, Gorchev G, Tsekova V, Grundker C, Gunthert AR, Hanker LC, Velikova M, Sindermann H, Engel J and Schally AV. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol. 2010; 119(3): 457-461.
33. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews Cancer. 2009; 9(5): 338-350.
34. Tewey KM, Rowe TC, Yang L, Halligan BD and Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984; 226(4673): 466-468.
35. Ogretmen B and Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nature reviews Cancer. 2004; 4(8): 604-616.
36. Morad SA and Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nature reviews Cancer. 2013; 13(1): 51-65.
37. Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR and Gulbins E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis: an international journal on programmed cell death. 2007; 12(8): 1533-1541.
38. Denard B, Lee C and Ye J. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. eLife. 2012; 1:e00090.
39. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical pharmacology. 1999; 57(7): 727-741.
40. Denard B, Seemann J, Chen Q, Gay A, Huang H, Chen Y and Ye J. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. Cell host & microbe. 2011; 10(1): 65-74.
41. Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, Prasad PN and Liebow C. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. Cancer research. 2000; 60(15): 4194-4199.
42. Speelmans G, Staffhorst RW, Steenbergen HG and de KruijffB. Transport of the anti-cancer drug doxorubicin across cytoplasmic membranes and membranes composed of phospholipids derived from Escherichia coli occurs via a similar mechanism. Biochimica et biophysica acta. 1996; 1284(2): 240-246.
43. Gunthert AR, Grundker C, Bongertz T, Schlott T, Nagy A, Schally AV and Emons G. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. American journal of obstetrics and gynecology. 2004; 191(4): 1164-1172.
44. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G and Rekasi Z. Peptide analogs in the therapy of prostate cancer. The Prostate. 2000; 45(2): 158-166.
45. Nagy A and Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biology of reproduction. 2005; 73(5): 851-859.
46. Hohla F, Buchholz S, Schally AV, Krishan A, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C and Seitz S. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett. 2010; 294(1): 35-42.
47. Pozsgai E, Schally AV, Halmos G, Rick F and Bellyei S. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res. 2010; 42(11): 781-786.
48. Seitz S, Buchholz S, Schally AV, Jayakumar AR, Weber F, Papadia A, Rick FG, Szalontay L, Treszl A, Koster F, Ortmann O and Hohla F. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anti-cancer drugs. 2013; 24(2): 150-157.
49. Seitz S, Schally AV, Treszl A, Papadia A, Rick F, Szalontay L, Szepeshazi K, Ortmann O, Halmos G, Hohla F and Buchholz S. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. Anticancer Drugs. 2009; 20(7): 553-558.
50. Treszl A, Schally AV, Seitz S, Szalontay L, Rick FG, Szepeshazi K and Halmos G. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides. 2009; 30(9): 1643-1650.
51. Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M and Rick FG. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]. Oncotarget. 2012; 3(7): 686-699.
52. Szepeshazi K, Schally AV and Halmos G. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. International journal of oncology. 2007; 30(6): 1485-1492.
53. Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A and Rick FG. Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108. Oncotarget. 2013; 4(5): 751-760.
54. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). International journal of cancer Journal international du cancer. 1978; 21(3): 274-281.
55. Bajo AM, Schally AV, Halmos G and Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(10 Pt 1):3742-3748.
56. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K and Armatis P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. Journal of the National Cancer Institute. 1997; 89(23): 1803-1809.
57. Emons G, Sindermann H, Engel J, Schally AV and Grundker C. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology. 2009; 90(1): 15-18.
58. Emons G, Gorchev G, Sehouli J, Wimberger P, Stahle A, Hanker L, Hilpert F, Sindermann H, Grundker C and Harter P. Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5). Gynecologic oncology. 2014; 133(3): 427-432.
59. Emons G, Gorchev G, Harter P, Wimberger P, Stahle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Grundker C, Sindermann H and Sehouli J. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2014; 24(2): 260-265.
60. Wang X, Krebs LJ, Al-Nuri M, Pudavar HE, Ghosal S, Liebow C, Nagy AA, Schally AV and Prasad PN. A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(20): 11081-11084.
61. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE and Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2011; 21(7): 440-446.
62. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ and Borowski E. Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncology research. 2003; 13(5): 245-252.
63. Doroshow JH. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proceedings of the National Academy of Sciences of the United States of America. 1986; 83(12): 4514-4518.
64. Wagner BA, Evig CB, Reszka KJ, Buettner GR and Burns CP. Doxorubicin increases intracellular hydrogen peroxide in PC3 prostate cancer cells. Archives of biochemistry and biophysics. 2005; 440(2): 181-190.
65. White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ and Voelkel-Johnson C. Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free radical biology & medicine. 2007; 43(9): 1313-1321.
66. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, Zarandi M, Groot K, Miyazaki M, Jungwirth A and Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(14): 7269-7273.
67. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S and Seitz S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A. 2012; 109(5): 1655-1660.
68. Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL and Hohla F. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle. 2012; 11(13): 2518-2525.
69. Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL and Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle. 2012; 11(22): 4203-4210.
70. Rick FG, Abi-Chaker A, Szalontay L, Perez R, Jaszberenyi M, Jayakumar AR, Shamaladevi N, Szepeshazi K, Vidaurre I, Halmos G, Krishan A, Block NL and Schally AV. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(7): 2617-2622.